Elevated serum BAFF levels in patients with sarcoidosis: Association with disease activity

Rheumatology (United Kingdom)

Volumn 52, Issue 9, 2013, Pages 1658-1666

  Ueda Hayakawa, Ikuko ^a   Tanimura, Hirotsugu ^a   Osawa, Manabu ^a   Iwasaka, Hiroshi ^a   Ohe, Shuichi ^a   Yamazaki, Fumikazu ^a   Mizuno, Kana ^a   Okamoto, Hiroyuki ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

B cell; B cell activating factor (BAFF); Monocyte; Sarcoidosis

Indexed keywords

B CELL ACTIVATING FACTOR; DIPEPTIDYL CARBOXYPEPTIDASE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4; LYSOZYME;

ADULT; AGED; ANGIOTENSIN BLOOD LEVEL; ARTICLE; B LYMPHOCYTE; CELL CULTURE; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIOID CELL; FEMALE; FLOW CYTOMETRY; HEP 2 CELL; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MONOCYTE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SARCOIDOSIS; SKIN GRANULOMA; SYSTEMIC LUPUS ERYTHEMATOSUS;

B CELL; B-CELL-ACTIVATING FACTOR (BAFF); MONOCYTE; SARCOIDOSIS;

AGED; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; BIOLOGICAL MARKERS; FEMALE; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-4; MALE; MIDDLE AGED; MONOCYTES; MURAMIDASE; PEPTIDYL-DIPEPTIDASE A; SARCOIDOSIS; SEVERITY OF ILLNESS INDEX;

EID: 84883040417     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ket186     Document Type: Article

References (33)

1. Agostini C, Adami F, Semenzato G. New pathogenetic insights into the sarcoid granuloma. Curr Opin Rheumatol 200012:71-6.
2. Newman LS, Rose CS, Maier LA. Sarcoidosis. N Engl J Med 1997336:1224-34.
3. Buckley CE, Nagaya H, Sieker HO. Altered immunologic activity in sarcoidosis. Ann Intern Med 196664:508-20.
4. Hunninghake GW, Crystal RG. Mechanisms of hypergammaglobulinemia in pulmonary sarcoidosis. Site of increased antibody production and role of T lymphocytes. J Clin Invest 198167:86-92.
5. Weinberg I, Vasiliev L, Gotsman I. Anti-dsDNA antibodies in sarcoidosis. Semin Arthritis Rheum 200029:328-31.
6. Daniele RP, McMillan LJ, Dauber JH et al. Immune complexes in sarcoidosis: a correlation with activity and duration of disease. Chest 197874:261-4.
7. Pettersson T. Rheumatic features of sarcoidosis. Curr Opin Rheumatol 19979:62-7.
8. Batten M, Groom J, Cachero TG et al. BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med 2000192:1453-66.
9. Schiemann B, Gommerman JL, Vora K et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 2001293: 2111-4.
10. Mackay F, Schneider P, Rennert P et al. BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol 200321: 231-64.
11. Mackay F, Woodcock SA, Lawton P et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999190:1697-710.
12. Groom J, Kalled SL, Cutler AH et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J Clin Invest 2002109: 59-68.
13. Cheema GS, Roschke V, Hilbert DM et al. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 200144: 1313-9.
14. Matsushita T, Hasegawa M, Yanaba K et al. Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum 200654:192-201.
15. Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med 2007357:2153-65.
16. Kasahara Y, Ashihara Y. Colorimetry of angiotensin-I converting enzyme activity in serum. Clin Chem 198127: 1922-5.
17. Ensink FTE, van Haeringen NJ. Pitfalls in the assay of lysozyme in human tear fluid. Ophthal Res 19779: 366-73.
18. Lieberman J. Elevation of serum angiotensin-convertingenzyme (ACE) level in sarcoidosis. Am J Med 197559: 365-72.
19. Pascual RS, Gee JB, Finch SC. Usefulness of serum lysozyme measurement in diagnosis and evaluation of sarcoidosis. N Engl J Med 1973289:1074-6.
20. Moore PA, Belvedere O, Orr A et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999285:260-3.
21. Nardelli B, Belvedere O, Roschke V et al. Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 200197:198-204.
22. Shigehara K, Shijubo N, Ohmichi M et al. Increased circulating interleukin-12 (IL-12) p40 in pulmonary sarcoidosis. Clin Exp Immunol 2003132:152-7.
23. Mizuno K, Okamoto H, Horio T. Heightened ability of monocytes from sarcoidosis patients to form multinucleated giant cells in vitro by supernatants of concanavalin A-stimulated mononuclear cells. Clin Exp Immunol 2001126:151-6.
24. Chu VT, Enghard P, Schürer S et al. Systemic activation of the immune system induces aberrant BAFF and APRIL expression in B cells in patients with systemic lupus erythematosus. Arthritis Rheum 200960:2083-93.
25. Sato S, Fujimoto M, Hasegawa M et al. Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells. Arthritis Rheum 200450:1918-27.
26. Okamoto H, Mizuno K, Horio T. Circulating CD14+ CD16+ monocytes are expanded in sarcoidosis patients. J Dermatol 200330:503-9.
27. Batten M, Groom J, Cachero TG et al. BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med 2000192:1453-66.
28. Meyer-Bahlburg A, Andrews SF, Yu KO et al. Characterization of a late transitional B cell population highly sensitive to BAFF-mediated homeostatic proliferation. J Exp Med 2008205:155-68.
29. Saussine A, Tazi A, Feuillet S et al. Active chronic sarcoidosis is characterized by increased transitional blood B cells, increased IL-10-producing regulatory B cells and high BAFF levels. PLoS One 20127:e43588.
30. Mackay F, Woodcock SA, Lawton P et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999190: 1697-710.
31. Zhang J, Roschke V, Baker KP et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001166:6-10.
32. Navarra SV, Guzmán RM, Gallacher AE et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011377:721-31.
33. Sanz I. Connective tissue diseases: targeting B cells in SLE: good news at last! Nat Rev Rheumatol 2011;7: 255-6.